Press Releases

Historic SomaLogic Press Releases >

Date	Title and Summary	Additional Formats
Feb 09, 2021	NIH Sponsored Study at Stanford University School of Medicine to Utilize Fluidigm Mass Cytometry Technology and Maxpar Direct Immune Profiling Assay to Evaluate Immune Responses in Pediatric Patients with COVID-19 Researchers Seek Insight into Development and Progression of Multisystem Inflammatory Syndrome in Children Study Exemplifies Increasing Use of CyTOF Technology in Clinical Research SOUTH SAN FRANCISCO, Calif. , Feb. 09, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative
Feb 04, 2021	Fluidigm to Participate in BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference SOUTH SAN FRANCISCO, Calif. , Feb. 04, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that the company’s management will participate in investor meetings at
Jan 26, 2021	Helix Specialty Diagnostics Partners with Genomic LTC DX to Provide COVID-19 Testing with Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay on Biomark HD Platform Major Midwest Labs Targeting 3,000 Tests per Day SOUTH SAN FRANCISCO, Calif. , Jan. 26, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that Helix Specialty
Jan 21, 2021	Fluidigm Receives CE-IVD Mark for Its Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay for COVID-19 SOUTH SAN FRANCISCO, Calif. , Jan. 21, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that the company has received the CE-IVD mark for its Advanta™ Dx
Jan 07, 2021	Fluidigm Announces Conference Call and Webcast of Fourth Quarter and Full Year 2020 Financial Results SOUTH SAN FRANCISCO, Calif. , Jan. 07, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report fourth quarter and full year 2020 financial results
Jan 05, 2021	New Data Published in Gastroenterology Demonstrate the Power of Fluidigm’s Imaging Mass Cytometry on the Hyperion Imaging System to Identify Novel Targets for Pancreatic Cancer Therapy Study Highlighting IMC Application in Both Protein and RNA Detection Conducted by Researchers at Fluidigm C enter of Excellence for Imaging Mass Cytometry at Georgetown Lombardi Comprehensive Cancer Center SOUTH SAN FRANCISCO, Calif. , Jan. 05, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation
Dec 15, 2020	Dr. Ana K. Stankovic, MD, PhD, Appointed to Fluidigm Board of Directors SOUTH SAN FRANCISCO, Calif. , Dec. 15, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the appointment of Dr. Ana K.
Nov 24, 2020	Key Regulatory Body in India Grants Commercial License for Fluidigm Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay Fluidigm Assay is Among First Saliva-Based COVID-19 Tests Licensed for Use by Designated Labs in India SOUTH SAN FRANCISCO, Calif. , Nov. 24, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive
Nov 20, 2020	Fluidigm to Participate at the Piper Sandler 32nd Annual Virtual Healthcare Conference SOUTH SAN FRANCISCO, Calif. , Nov. 20, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that the company’s management will participate in the Piper Sandler
Nov 19, 2020	Study Utilizing Imaging Mass Cytometry Details Changes in Lung Tissue Architecture at the Single-Cell Level in Patients with COVID-19 Weill Cornell Medicine Researchers Utilize Fluidigm Hyperion Imaging System to Identify a Phenotype of Immune Cell Activity Distinct from Other Lung Infections A Framework for Data-Driven Spatial Understanding of Lung Pathology to Inform New Treatment Approaches for COVID-19 SOUTH SAN FRANCISCO,